Publications by authors named "M Grigoriou"
• Aging leads to chronic inflammation and immune dysfunction, heightening the risk of myeloid malignancies like MDS and CMML. • Both aging and MDS show alterations in monocyte subtypes and function. Aging boosts inflammatory genes upregulation, whereas MDS favors antigen presentation, reflecting distinct immune and disease-specific adaptations.
View Article and Find Full Text PDFMolecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways.
Ann Rheum Dis
November 2024
Article Synopsis
- The study investigates how belimumab, a drug for systemic lupus erythematosus (SLE), affects blood gene expression and whether early treatment response can be predicted through blood tests.
- RNA sequencing was conducted on blood samples from 45 active SLE patients before and after 6 months of treatment, revealing significant changes in gene expression related to immune cell activity and disease severity.
- Results indicate that belimumab reduces specific immune pathways and may reverse disease markers, with a model predicting treatment response based on 50 genes showcasing 84% accuracy.
Article Synopsis
- CD8+ T cells play a vital role in fighting cancer, but their functionality is compromised in higher-risk myelodysplastic neoplasms (HR-MDS) and acute myeloid leukemia (AML).
- An analysis of 104 pre-treatment bone marrow samples revealed that patients who did not respond to azacitidine therapy had higher levels of a specific CD8+ T cell subset (CD57+CXCR3+), which was linked to worse survival outcomes.
- The study also highlighted that successful treatment responses were associated with stronger IFN signaling, while non-responders showed increased TGF-β signaling, suggesting that combining TGF-β inhibitors with azacitidine could improve treatment in these cancer types.
Introduction: Immune checkpoint blockade (ICB) immunotherapy has revolutionized cancer treatment, demonstrating exceptional clinical responses in a wide range of cancers. Despite the success, a significant proportion of patients still fail to respond, highlighting the existence of unappreciated mechanisms of immunotherapy resistance. Delineating such mechanisms is paramount to minimize immunotherapy failures and optimize the clinical benefit.
View Article and Find Full Text PDFBone marrow has raised a great deal of scientific interest, since it is responsible for the vital process of hematopoiesis and is affiliated with many normal and pathological conditions of the human body. In recent years, organs-on-chips (OoCs) have emerged as the epitome of biomimetic systems, combining the advantages of microfluidic technology with cellular biology to surpass conventional 2D/3D cell culture techniques and animal testing. Bone-marrow-on-a-chip (BMoC) devices are usually focused only on the maintenance of the hematopoietic niche; otherwise, they incorporate at least three types of cells for on-chip generation.
View Article and Find Full Text PDF